Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel
NASDAQ:APMD

Apnimed Q2 2026 Earnings Report

Apnimed logo
$21.91 -1.99 (-8.33%)
As of 09/30/2026 04:00 PM Eastern
ProfileEarnings HistoryForecast

Apnimed EPS Results

Actual EPS
$0.51
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Apnimed Revenue Results

Actual Revenue
$12.08 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Apnimed Announcement Details

Quarter
Q2 2026
Date
9/8/2026
Time
After Market Closes
Conference Call Date
Tuesday, September 8, 2026
Conference Call Time
7:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Apnimed's Q2 2026 Press ReleasePress Release
(8-K)
Apnimed's Q2 2026 Quarterly reportQuarterly report
(10-Q)

Apnimed Earnings Headlines

Apnimed, Inc. (NASDAQ:APMD) Receives Average Recommendation of "Moderate Buy" from Brokerages
September 22, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31039349
Apnimed: What We Know Heading Into The Feb PDUFA
September 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4944861-apnimed-q2-what-we-know-heading-into-the-feb-pdufa
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
October 1 at 1:00 AM  |  Chaikin Analytics (Ad)
Apnimed Swings To Q2 Profit, Eyes February 2027 FDA Decision On AD109 In Obstructive Sleep Apnea
September 9, 2026  |  rttnews.comhttps://www.rttnews.com/3689452/apnimed-swings-to-q2-profit-eyes-february-2027-fda-decision-on-ad109-in-obstructive-sleep-apnea.aspx
Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3358140/0/en/apnimed-reports-second-quarter-2026-financial-results-and-provides-corporate-update.html
Apnimed Inc
September 5, 2026  |  markets.ft.comhttps://markets.ft.com/data/equities/tearsheet/summary?s=APMD:NSQ
See More Apnimed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Apnimed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Apnimed and other key companies, straight to your email.

About Apnimed

Apnimed (NASDAQ:APMD) Inc. is a clinical-stage pharmaceutical company focused on developing oral medicines for sleep apnea. The company is working to provide pharmacologic alternatives to device-based treatments for patients with obstructive sleep apnea, a condition involving repeated interruptions in breathing during sleep.

Apnimed’s lead candidate is AD109, an investigational once-daily combination of atomoxetine and aroxybutynine. The therapy is designed to improve the activity of muscles that help keep the upper airway open during sleep. AD109 has been evaluated in clinical studies involving adults with obstructive sleep apnea, including patients who may be unable or unwilling to use continuous positive airway pressure therapy.

The company’s operations have centered on clinical development and regulatory advancement in the United States, with its programs intended for potential use in broader sleep-medicine markets. Apnimed is headquartered in the United States and has been led by Chief Executive Officer Larry Miller. As an investigational pharmaceutical company, Apnimed does not yet have an approved commercial product.

View Apnimed Profile
Earnings Tools